Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arca Biopharma Inc (ABIO)

Arca Biopharma Inc (ABIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the...

ABIO : 4.27 (+1.91%)
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial...

ABIO : 4.27 (+1.91%)
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

-- Initiation of Phase 2b clinical trial anticipated in Q4 2020

ABIO : 4.27 (+1.91%)
ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced the promotion...

AMGN : 229.21 (+1.83%)
ABIO : 4.27 (+1.91%)
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced it has...

ABIO : 4.27 (+1.91%)
ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19

ARCA anticipates filing an IND for AB201 for COVID-19 in September 2020 and initiating Phase 2B clinical testing as early as Q4 2020

ABIO : 4.27 (+1.91%)
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update

-- ARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4 2020

ABIO : 4.27 (+1.91%)
ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering

ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced...

ABIO : 4.27 (+1.91%)
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More

The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.

IRWD : 11.67 (-1.68%)
REGN : 510.00 (-0.79%)
GILD : 61.40 (+0.46%)
ABIO : 4.27 (+1.91%)
NTLA : 39.89 (+4.70%)
PHAS : 3.83 (unch)
ARCA Biopharma Announces $9.4 Million Registered Direct Offering

ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced...

ABIO : 4.27 (+1.91%)
Company News for May 29, 2020

Companies In The News Are: ABIO, ARPO, LL, DLTR

DLTR : 111.83 (-0.50%)
LL : 27.37 (-2.77%)
ABIO : 4.27 (+1.91%)
ARPO : 1.7062 (+0.36%)
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy

-- AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19

ABIO : 4.27 (+1.91%)
Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions

New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence

ABIO : 4.27 (+1.91%)
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial...

ABIO : 4.27 (+1.91%)
ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial...

ABIO : 4.27 (+1.91%)
ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial...

ABIO : 4.27 (+1.91%)
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Dr....

ABIO : 4.27 (+1.91%)
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Gencaro...

ABIO : 4.27 (+1.91%)
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc. ("Abiomed" or "the Company") (NASDAQ: ABMD) for violations of §§10(b)...

ABIO : 4.27 (+1.91%)
ABMD : 266.96 (-0.47%)
ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update

-- FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fraction (HFpEF)

ABIO : 4.27 (+1.91%)

Van Meerten Stock Picks

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar